Johnson and Johnson reported a complete response for 16 of 22 patients in their Phase II trial of a new approach for bladder cancer—the most expensive malignancy to treat over the lifetime of patients. The trial used TAR-200, an implantable pretzel-shaped device originally developed in the Cima Lab, to replace standard regimens with continuously administered gemcitabine in the bladder.